In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International Murex Gets What It Wants

Executive Summary

The $234 million purchase of International Murex Technologies Corp. by Abbott Laboratories may seem like a pricey deal, but it isn't if one considers that the whole of Murex is worth more than the sum of its parts. Murex has no stellar technology, but rather a broad portfolio of niche tests in virology and infectious diseases. Abbott is interested in Murex' blood banking business, its rapid HIV diagnostic assay, its attractive patent portfolio, and its microtiter plate technology.

You may also be interested in...



Innogenetics' New Chief Speaks Out

Philippe Archinard was one of the top executives at bioMerieux, the eighth largest diagnostics company, and a potential heir to Alain Merieux, the company's founder, when he left following disagreements with the new head of the company. He took a position as CEO of Innogenetics, a once high-flying biotech company with a strong emphasis on vaccines and molecular diagnostics. His mission: to fix the company's infrastructure so that it could grow, refocus its resources, and beef up its distribution in the wake of a disruption which occurred when its distribution and alliance partner International Murex was acquired by Abbott Labs in 1998.

IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher

New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.

Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel